\nAVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO\u2019s commercial strategy and operations, including the commercialization of FOTIVDA\u00ae<\/sup> (tivozanib). FOTIVDA is AVEO\u2019s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.\n<\/p>\n
\n\u201cDirectly on the heels of FOTIVDA\u2019s approval, it is a pleasure to announce Mike\u2019s appointment to chief commercial officer,\u201d said Michael Bailey, president and chief executive officer of AVEO. \u201cMike\u2019s hard work and dedication has played a crucial role in preparing for our evolution to a commercial organization. I look forward to working with Mike in his new role as we continue to execute on our mission of improving the lives of patients with cancer.\u201d\n<\/p>\n
\n\u201cIt is an honor to be taking on this new role at such an exciting time for the Company,\u201d said Mr. Ferraresso. \u201cI look forward to continuing to contribute to our evolution into a commercial organization.\u201d\n<\/p>\n
\nMr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations. He has over 20 years of commercial pharmaceutical and biotechnology experience, including 15 years developing and commercializing oncology products. At AVEO, in addition to developing the Company\u2019s commercial strategy and infrastructure, Mr. Ferraresso has played a key role in business development activities, including the Company\u2019s immuno-oncology clinical collaborations and the over $400 million agreement amendment with Kyowa Kirin for non-oncology rights to tivozanib in AVEO\u2019s territories. Prior to joining AVEO, he served in sales and commercial operations roles of increasing responsibility at several biotechnology and pharmaceutical companies, including at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics, and Muro Pharmaceuticals. Mr. Ferraresso has extensive experience in commercial strategy including partnerships, development, pricing, and field deployment models and has launched Oprapred\u2122, Plenaxis\u2122, Zyflo\u2122 and Feraheme\u2122. Mr. Ferraresso holds a BA degree in Economics from Assumption College.\n<\/p>\n
About FOTIVDA\u00ae<\/sup> (tivozanib)<\/b><\/p>\n \nFOTIVDA\u00ae<\/sup> (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma (UK) Limited for the treatment of adult patients with advanced RCC. FOTIVDA has been shown to significantly reduce regulatory T-cell production in preclinical models1<\/sup>. FOTIVDA was discovered by Kyowa Kirin.\n<\/p>\n About AVEO Pharmaceuticals, Inc. <\/b><\/p>\n \nAVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO\u2019s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO\u2019s lead candidate, FOTIVDA\u00ae<\/sup> (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA\u00ae<\/sup> was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO\u2019s pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO\u2019s earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.\n<\/p>\n Cautionary Note Regarding Forward Looking Statements <\/b><\/p>\n \nThis press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cseek,\u201d \u201clook forward,\u201d \u201cadvance,\u201d \u201cgoal,\u201d \u201cstrategy,\u201d or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: AVEO\u2019s planned timing for making FOTIVDA available to patients in the U.S.; the potential for FOTIVDA as a treatment option for patients with relapsed\/refractory or advanced RCC; the potential efficacy, safety, and tolerability of FOTIVDA, both as a stand-alone drug candidate and in combination with immunotherapy; AVEO\u2019s execution of its clinical and regulatory strategy for FOTIVDA; AVEO\u2019s plans and strategies for current and future clinical trials of FOTIVDA, ficlatuzumab and AV-380 and for commercialization of FOTIVDA in the United States; the advancement of AVEO\u2019s pipeline, including the advancement of ficlatuzumab in multiple clinical studies; the potential efficacy, safety and tolerability of ficlatuzumab, both as a stand-alone drug candidate and in combination with other therapies; the potential outcomes from studies of ficlatuzumab to provide AVEO with opportunities to pursue regulatory strategies; the potential clinical utility of ficlatuzumab in areas of unmet need; and AVEO\u2019s strategy, prospects, plans and objectives for its product candidates and for the Company generally. AVEO has based its expectations and estimates on assumptions that may prove to be incorrect. As a result, readers are cautioned not to place undue reliance on these expectations and estimates. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEO\u2019s ability to successfully implement its strategic plans, including its ability to successfully commercialize FOTIVDA and to obtain and maintain market and third party payor acceptance of FOTIVDA; AVEO\u2019s ability to raise the substantial additional funds required to successfully commercialize FOTIVDA; AVEO\u2019s ability, and the ability of its licensees, to demonstrate to the satisfaction of applicable regulatory agencies such as the FDA the safety, efficacy and clinically meaningful benefit of AVEO\u2019s product candidates, and risks relating to the timing and costs of seeking and obtaining regulatory approvals; AVEO\u2019s dependence on third-party vendors for the development, manufacture and supply of FOTIVDA and its product candidates; AVEO\u2019s ability to enter into and maintain its third party collaboration and license agreements, and its ability, and the ability of its strategic partners, to achieve development and commercialization objectives under these arrangements; AVEO\u2019s and its collaborators\u2019 ability to successfully enroll and complete clinical trials; AVEO\u2019s ability to maintain compliance with regulatory requirements applicable to FOTIVDA and its product candidates; AVEO\u2019s ability to obtain and maintain adequate protection for intellectual property rights relating to FOTIVDA and its product candidates; unplanned capital requirements; uncertainties related to AVEO\u2019s ability to access future borrowings under the Hercules loan facility, which turns on the achievement of milestones related to the commercialization of FOTIVDA in the U.S.; adverse general economic, political, and industry conditions; the potential adverse effects of the COVID-19 pandemic on AVEO\u2019s business continuity, financial condition, results of operations, liquidity and ability to successfully and timely enroll, complete and read-out data from its clinical trials; competitive factors; and those risks discussed in the sections titled \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u2014Liquidity and Capital Resources\u201d included in AVEO\u2019s quarterly and annual reports on file with the Securities and Exchange Commission (SEC) and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO\u2019s views as of the date of this press release, and subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.\n<\/p>\n \nAny reference to AVEO\u2019s website address in this press release is intended to be an inactive textual reference only and not an active hyperlink.\n<\/p>\n References:<\/b><\/p>\n \n1. Pawlowski N et al. AACR 2013. Poster 3971\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210310006000\/en\/<\/a><\/span><\/p>\n AVEO Public Relations: AVEO Investor Relations: KEYWORDS:<\/b> United States North America Canada Massachusetts<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<\/p>\n
\n<\/b>
David Pitts, Argot Partners
\n
(212) 600-1902
\n
aveo@argotpartners.com<\/a><\/p>\n
\n<\/b>
Hans Vitzthum, LifeSci Advisors
\n
(617) 430-7578
\n
hans@lifesciadvisors.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210310006000\/en\/469950\/3\/AVEO_NEW_LOGO.jpg\"){kind=logo}
<\/td>\n<\/tr>\n